Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

European Neuropsychopharmacology

Volumn 21, Issue 12, 2011, Pages 867-875

  Arango, Celso ^a   Bobes, Julio ^b   Kirkpatrick, Brian ^c   Garcia Garcia, Margarida ^d   Rejas, Javier ^e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Operations Department   (Spain)

^e PFIZER INC   (United States)

Author keywords

Antipsychotic treatment; Cardiovascular disease; Deficit schizophrenia; Negative symptoms; Outpatients; Schizophrenia

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORTALITY; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 82855161486     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.03.005     Document Type: Article

References (29)

1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
3. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. Eur. Psych. 2010, 10.1016/j.eurpsy.2010.09.001.
4. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr. Res. 2007, 90:162-173.
5. Carpenter W. Unmet therapeutic needs. Schizophr. Bull. 2005, 31:793-794.
6. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145:578-583.
7. Chuang H.T., Mansell C., Patten S.B. Lifestyle characteristics of psychiatric outpatients. Can. J. Psychiatry 2008, 53:260-266.
8. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003, 24:987-1003.
9. Després J.P., Moorjani S., Lupien P.J., Tremblay A., Nadeau A., Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990, 10:497-511.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 16; 285: 2486-2497.
11. Goff D., Sullivan L., McEvoy J., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80:45-53.
12. Guy W. Early Clinical Drug Evaluation (ECDEU). Assessment Manual 1976, Nat. Inst. Ment. Health, Rockville.
13. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
14. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T., et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr. Res. 1996, 20:69-77.
15. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Depressive symptoms and the deficit syndrome of schizophrenia. J. Nerv. Ment. Dis. 1994, 182(8):452-455.
16. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Case identification and stability of the deficit syndrome of schizophrenia. Psych. Res. 1993, 47:47-56.
17. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989, 30:119-123.
18. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58:165-171.
19. Kirkpatrick B., Fernandez-Egea E., Garcia-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophr. Res. 2009, 107(2-3):122-127.
20. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Alméras N., et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men?. Circulation 2000, 102:179-184.
21. Moreno C., Merchan-Naranjo J., Alvarez M., Baeza I., Alda J.A., Martinez-Cantarero C., Parellada M., Sanchez B., de Giraldez M., Arango C. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Moreno et al. Bipolar Disord. 2010, 12:172-184.
22. National Institutes of Health Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421.
23. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch. Gen. Psychiatry 2007, 64(2):242-249.
24. Peralta V., Cuesta M. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1994, 22:171-177.
25. Pouliot M.C., Després J.P., Lemieux S., Moorjani S., Bouchard C., Tremblay A., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 1994, 73:460-468.
26. SEA Obesidad y riesgo cardiovascular. Documento consenso. Sociedad Española de Arterioesclerosis 2003.
27. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
28. Van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006, 113:91-95.
29. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1988, 97:1837-1847.